biostudies-literaturePechlivani NBritish Heart FoundationDiabetes UKWellcome Trust89-100https://www.ebi.ac.uk/biostudies/studies/S-EPMC11742610biostudies-literatureUnknown9(1)<h4>Abstract</h4>Hypofibrinolysis is a documented abnormality in conditions with high risk of vascular occlusion. A key inhibitor of fibrinolysis is α2-antiplasmin (α2AP), and we hypothesize that the Affimer technology, comprising small conformational proteins with 2 9-amino-acid variable regions, can be used to modulate α2AP activity and facilitate fibrinolysis. Using a phage display system, a library of Affimers was screened against α2AP. A total of 28 α2AP-specific Affimers were isolated, of which 1, termed Affimer A11, inhibited protein function and enhanced fibrinolysis. Affimer A11 displayed a monomeric form and consistently reduced the lysis time of clots made from plasma samples of individuals with type 2 diabetes mellitus (n = 15; from 150.8 ± 100.9 to 109.8 ± 104.8 minutes) and tBlood advancesUse of Affimer technology for inhibition of α2-antiplasmin and enhancement of fibrinolysis.PMC11742610FS/IBSRF/22/2513014/0005006Tomlinson DCAlmutairi MTiede CPonnambalam SAlsayejh BKietsiriroje NDuval CSimmons KGaule TAjjan RAPechlivani NPhoenix FAriens RASfalseUse of Affimer technology for inhibition of α2-antiplasmin and enhancement of fibrinolysis.<h4>Abstract</h4>Hypofibrinolysis is a documented abnormality in conditions with high risk of vascular occlusion. A key inhibitor of fibrinolysis is α2-antiplasmin (α2AP), and we hypothesize that the Affimer technology, comprising small conformational proteins with 2 9-amino-acid variable regions, can be used to modulate α2AP activity and facilitate fibrinolysis. Using a phage display system, a library of Affimers was screened against α2AP. A total of 28 α2AP-specific Affimers were isolated, of which 1, termed Affimer A11, inhibited protein function and enhanced fibrinolysis. Affimer A11 displayed a monomeric form and consistently reduced the lysis time of clots made from plasma samples of individuals with type 2 diabetes mellitus (n = 15; from 150.8 ± 100.9 to 109.8 ± 104.8 minutes) and t2025-01-01T00:00:00Z2025 Jan2026-06-02T20:11:34.592Z2025-04-04T14:05:56.518ZS-EPMC117426103950455910.1182/bloodadvances.2024014235